Providing sponsors with innovative processes including protocol design, site training, and real-time data quality analysis

Clinical understanding of neurobiology is incomplete, contributing to central nervous system (CNS) clinical development programmes having among the highest failure rates across all therapeutic areas. CNS clinical trials bring specific challenges, including managing placebo response, incorporating soft endpoints, and require a particular focus on reducing patient burden.

Unsurprisingly this had led to a challenging of accepted and established norms by CNS drug developers.

We support sponsors in minimising development risk and maximising probability of success through:

  • Access to the latest, applied technology innovation and processes
  • Working with our highly qualified and therapeutically trained staff
  • Real time data quality monitoring and analysis
  • 150,900+

    Patients involved
  • 830+

  • 21,000+


Services for CNS, Pain and Ageing Diseases

Our Protocol Optimisation and Clinical Development Plans service is complemented with Adaptive Design competency. Our full-service study/program implementation and execution include: 


Dedicated specialist teams

All staff assigned to projects, including project management, drug development, site identification, feasibility, and medical oversight attend customised training programs. Over the past five years, ICON have conducted phase I, II & III studies in various CNS indications. We also offer dedicated teams for rare and paediatric CNS programs.

CNS, pain and ageing related disorders insights

ICON's experienced neuroscience and drug development teams regularly share their insights in industry publications and through ICON produced content in the form of blogs and whitepapers. Read more content from our experts.

Read more